Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.11+0.02 (+0.12%)
At close: 4:00PM EDT
16.11 0.00 (0.00%)
After hours: 04:20PM EDT
Advertisement
Sign in to post a message.
  • O
    O-Behave
    $BIIB conversation
    This is the LAST TIME you will see $BIIB this low. Did you see that $48 million BUY yesterday? We could close WELL above $305 today. Yesterday I said ALL savy biotech traders of stocks like $NOVN $PROG $VXRT $BIVI $EVFM $GBS $CLSN $PTGX $ANVS $SAVA $AUTL $NNVC $ENZN $DRNA $PULM $KMPH $APTX $EOLS $RNLX $VKTX $ORPH $APTO $GLTO $HTBX $FMTX $EQ $VRTX $SYN $CAPA $KLDO $TARS $INZY $FLGT $CVAC $XFOR $ACRS $SANA $JNJ $MRK $MRNA $REGN $LLY etc should be loading $BIIB with both hands. I hope they listened. The trend is BULLISH again. If u can't tell. NEW ANALYST Neddham initiated a BUY coverage Yesterday with a target price of $400! $400 is kinda low to me but at least it's better than where $BIIB is now! Free money 💰 imo.
    Bullish
  • m
    mark
    When I see big institution ownership and few retail posters I know this equity is going higher!
  • m
    mark
    Major hedgefund ownership in ACRS which is the smart money. Once retail becomes aware of this equity it will be north of 25 quickly.
  • m
    mark
    Check out Hedge Fund VR ADVISER, LLC. This fund manages 1.5 Billion for 7 clients and they specialize in health care. Of the 36 Health Care/Bios they own, their 2nd largest holding is ACRS. They hold 4,563,962 shares representing 8.75% of the outstanding shares. On 6-30 they added 843,380 shares.

    When you have Hedge Funds making big bets on pipeline bios you know they have done their homework.

    Long and Strong ACRS!
  • Y
    Yahoo Finance Insights
    Aclaris Therapeutics is up 7.07% to 15.30
  • G
    Greenberg
    BRUTAL Hot Rebound Play which is massive underpriced here trading wayyy below cash

    ACRS = Market Cap $43 M / Cash $115 M or untill end 2021 / 1 Marketed Product / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Prodcuts which means HUGE upfront payments forthe company (more infos below)= CHEAPEST Biotech you can get at this time

    Aclaris Therapeutics (ACRS)

    Market Cap: $43 M
    Cash: $115 M or enough untill end 2021

    Aclaris Therapeutics Announces New Strategic Direction
    https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-new-strategic-direction

    Pipeline
    https://www.aclaristx.com/pipeline/

    Largest Shareholders:

    Deerfield Management Company LP...5 893 416
    Franklin Advisers, Inc....3 953 203
    BlackRock Fund Advisors ...2 359 223
    Broadfin Capital LLC...2 280 260
    D. E. Shaw & Co. LP....2 049 462
    Sofinnova Ventures, Inc.....1 911 573
    Vivo Capital LLC ....1 647 214
    Fidelity Management & Research Co...1 562 190
    Polar Capital LLP...1 443 920
    The Vanguard Group, Inc...1 142 022
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    investor.aclaristx.com
  • f
    frank
    I am long and so I don't care much for the S-T price movement, but it's not very convincing as to why the price continues to drop. ACRS has already one product called RHOFADE, approved by the U.S. Food and Drug Administration, or FDA, in January 2017 and started to create revenue through Allergan which distributes RHOFADE. They are also currently seeking a strategic partner to commercialize ESKATA, both in the United States and worldwide and indicated that this decision was due to the fact that revenues from product sales were insufficient for them to sustain continued commercialization as a result of the product not achieving sufficient market acceptance by physicians and patients, and not for efficacy or safety reasons. Thus, this product is not totally a failure. Finally, they have a strong pipeline which includes 1) recent announcement - a positive results from its Phase 3 clinical trial for an investigational new drug for the treatment of common warts, 2) total five phase 2 therapeutic indications currently undergoing plus various other programs. ACRS has a solid financial position for another 2 years while the products just developed started to bring more cash. Not sure why these potentials are overlooked.
  • R
    ROBERT
    Just sold half my position (4000 of 8000) - cost basis $1.12. Will buy back between 7 and 8.
  • F
    Food4Thought
    Just because the company issued an offering of 17.50 doesn't mean they will sell..
    Public offering vs direct placement offering is vastly different. One assumes that there will be buyers on the market, while the other has already found a buyer. I would think any major institution would avoid this as it is NOT close to having a product and is asking a premium of 3x its stock price from earlier this week...
  • G
    Greenberg
    Market Cap $51 Million / Cash $115 Million or untill late 2021 / 2 Approved Drugs / Another one with STRONG phase 3 results / Eskata approvalin Canada within 3 Weeks will trigger Milestone payments to ACRS / More Licensing Deals for5 Drugs = Upfront Payments and second Phase 3 readout during Q4 = TOP PICK 2019 can hit $5 very quickly with good news
  • G
    Greenberg
    Market Cap laughable $55 Million ---Cash $115 Million or untill late 2021 EXLCUDING cash from expected partnering which is imminent _ 2 APPROVED DRUGS - Another one with STRONG P3 DATA earlythis week and many more in phase 2 programs =PURE LIFETIME OPP
  • J
    Jonnie
    I feel like I’m missing out but why isn’t this breaking out of $2 with all the good news?
  • k
    kenneth
    Obviously people knew about this offering during the day on Monday before the announcement. I was buying while they were selling. They obviously also knew the pricing on this offering as it ironically closed right there. Company may have great science but they need a little work on their compliance
  • t
    tigerstocks
    ACRS will host an R&D day for analysts and investors TOMORROW! gues what, do you think a company will take part on a conference to tell that they did bad things - i dont thinks so - the opposite is the case! To anounce A POSITIVE NEWS today would be a good timing, to have the attention tomorrow at the conference! STRONG BUY - good entry point (buy low and sell high)

    WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug candidates for immuno-inflammatory diseases on Friday, September 27, 2019 from 8:00 AM to 11:00 AM in New York, New York.

    https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-hold-rd-day
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    investor.aclaristx.com
  • G
    Greenberg
    Here are the largest Shareholders // Morgan Stanley bought over 2 million shares 3 weeks ago

    Deerfield Management Company LP...5 893 416
    Franklin Advisers, Inc....3 953 203
    BlackRock Fund Advisors ...2 359 223
    Broadfin Capital LLC...2 280 260
    D. E. Shaw & Co. LP....2 049 462
    Sofinnova Ventures, Inc.....1 911 573
    Vivo Capital LLC ....1 647 214
    Fidelity Management & Research Co...1 562 190
    Polar Capital LLP...1 443 920
    The Vanguard Group, Inc...1 142 022
  • G
    Greenberg
    seeking alpha LOL the most of the writers there a have terrible track record and BTW every loser can write an article there .AGAIN as a result of the strategic change the burn-rate will drop massive so their $115 million will lasts untill late 2021 EXCLUDING potential Upfront payments and Royalties from partnering of their Products . Ii know that this stock is super brutally underpriced im over 22 years active in the biotech sector so i dont need a wannabe analyst from seeking alpha with laughable 44 followers LOL who has no clue about biotechs .

    Aclaris anticipates that its current cash and cash equivalents will be sufficient to fund its operations into the third quarter of 2021, without giving effect to any potential new business development transactionshttps://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-new-strategic-direction
    “We believe this change in strategy will benefit Aclaris in the near term by lowering expenses and eliminating the inherent risks and investment related to maintaining a commercial infrastructure. By actively seeking a commercialization partner for our commercial products business and refocusing our resources with a view to optimizing our immuno-inflammatory development portfolio, we believe we can significantly reduce our costs, strengthen the organization, and extend our cash runway,” said Dr. Walker. “Our resources can now be dedicated to prudently advancing our pipeline of novel drug candidates for immuno-inflammatory diseases.”

    “As part of our new business strategy, we have approved a plan to significantly reduce our workforce. We expect to complete this reduction over the course of the next six months. This decision was extremely difficult but necessary. I would like to personally thank all of the affected employees for their contributions over the past years,” said Dr. Walker.
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Aclaris Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
    investor.aclaristx.com
  • M
    Mousa
    All things come to those who wait. Long and strong strong
    Bullish
  • K
    Keith
    It looks like institutional investors are slowly accumulating in the morning while individual retailors are selling. Most of ACRS shares are owned by big funds. Be patient and go long. This company will give you a big reward.
  • K
    Kevin
    Rising because they got an expert team put together for RA which means Very positive news coming for ATI-450 RA treatment and will move on the phase 3. ATI-450 for Covid-19 is coming soon as well. PT $30+
    Bullish
  • D
    D.Jones
    This are very good news fot the company! Strong phase 3 Results!! My target for the next time is 5$
Advertisement
Advertisement